Loading...
XNAS
SMTI
Market cap222mUSD
Jul 09, Last price  
23.88USD
1D
-1.44%
1Q
44.46%
Jan 2017
530.08%
Name

Sanara Medtech Inc

Chart & Performance

D1W1MN
XNAS:SMTI chart
P/E
P/S
2.12
EPS
Div Yield, %
Shrs. gr., 5y
8.50%
Rev. gr., 5y
45.92%
Revenues
103m
+18.97%
189,755630,505290,183288,021910,4202,209,6851,173,5441,726,3922,632,6433,372,1885,507,8536,304,7415,837,83911,766,76315,586,97624,143,91945,842,84564,989,84186,672,425103,117,982
Net income
-38m
L+288.66%
-623,559-542,756-1,773,196-2,302,527-5,135,491-12,740,816-1,845,323-4,148,088-2,278,177-1,340,455-415,747331,309-600,574-2,814,088-4,356,440-7,921,914-7,937,497-4,303,197-9,664,547-37,562,606
CFO
7m
P
-398,970-380,898-1,058,436-1,295,517-1,492,867-343,601-1,226,181-1,821,981-1,686,685-1,202,889409,245-139,862277,142-2,167,401-4,034,518-4,814,526-5,554,870-3,245,556-23,7846,786,629

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.
IPO date
Apr 07, 1994
Employees
101
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT